[Circulating galactomannan screening for early diagnosis and treatment of invasive aspergillosis].
OBJECTIVE
To explore the value of circulating galactomannan (GM) screening for early diagnosis and treatment monitoring of invasive aspergillosis (IA).


METHODS
Serum samples from 141 IA patients for the detection of GM by Platelia Aspergillus (Bia-Rad) were collected before and after systematic anti-fungal therapy.


RESULTS
(1) An increase in the clinical diagnosis rate of IA was obtained on the result of GM detection. The GM positivity appeared (10+/-4.1) (8-15) d before positive sputum culture, while (12.6+/-5.7) (6-22) d before the CT positive image. (2) Among the 62 patients with consecutive serum samples, 50 were success in treatment and 12 died. A progressive decrease of GM level was found in the former group, while the rising antigen titres were found in the latter.


CONCLUSIONS
Compared with other diagnostic test, GM test has an obvious advantage of higher positivity and earlier result. The anti-fungal effectiveness can be estimated by dynamic detection of serum GM.
Yao
Jia-feng
JF
Institute of Hematology & Blood Disease Hospital, CAMS & PAMS, Tianjin 300020, China.
Su
Dong
D
Huang
Yong
Y
Zhang
Ping
P
Lin
Qing-song
QS
Wang
Zhi-yong
ZY
Feng
Si-zhou
SZ
Han
Ming-zhe
MZ
D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001228:Aspergillosis / Q000097:blood / Q000175:diagnosis*; D042241:Early Diagnosis; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D005690:Galactose / Q000031:analogs & derivatives; D006801:Humans; D008297:Male; D008351:Mannans / Q000097:blood*; D008875:Middle Aged; D055815:Young Adult
D008351:Mannans; C012990:galactomannan; D005690:Galactose